{"id":"dc-aml-vaccine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Chills"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL3931570","moleculeType":"Small molecule","molecularWeight":"307.39"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine is designed to stimulate the immune system to recognize and attack cancer cells with specific mutations. Each vaccine is tailored to the individual patient's unique mutation profile.","oneSentence":"DC AML Vaccine is a personalized cancer vaccine that targets specific mutations in acute myeloid leukemia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:21.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT03059485","phase":"PHASE2","title":"DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-06-01","conditions":"Acute Myelogenous Leukemia","enrollment":82},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT03679650","phase":"PHASE1","title":"Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-10-11","conditions":"Acute Myelogenous Leukemia","enrollment":28},{"nctId":"NCT01096602","phase":"PHASE2","title":"Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2010-05","conditions":"Acute Myelogenous Leukemia, AML","enrollment":63},{"nctId":"NCT01898663","phase":"PHASE1, PHASE2","title":"DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML","status":"RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2013-06","conditions":"High-risk Soft Tissue Sarcoma","enrollment":30},{"nctId":"NCT01686334","phase":"PHASE2","title":"Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zwi Berneman","startDate":"2012-10","conditions":"Acute Myeloid Leukemia","enrollment":130},{"nctId":"NCT05000801","phase":"NA","title":"Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2021-07-01","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT01483274","phase":"PHASE1","title":"Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2015-03","conditions":"Acute Myelogenous Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DC AML Vaccine","genericName":"DC AML Vaccine","companyName":"Beth Israel Deaconess Medical Center","companyId":"beth-israel-deaconess-medical-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"DC AML Vaccine is a personalized cancer vaccine that targets specific mutations in acute myeloid leukemia. Used for Acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}